Bone Biologics Corporation
BBLG · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,130 | $6,908 | $1,579 | $82 |
| G&A Expenses | $2,089 | $2,520 | $0 | $0 |
| SG&A Expenses | $2,089 | $2,520 | $2,086 | $1,021 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,219 | $9,428 | $3,665 | $1,103 |
| Operating Income | -$4,219 | -$9,428 | -$3,665 | -$1,103 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $107 | $480 | $2,181 | -$508 |
| Pre-Tax Income | -$4,112 | -$8,949 | -$1,485 | -$1,611 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,112 | -$8,949 | -$1,485 | -$1,611 |
| % Margin | – | – | – | – |
| EPS | -4.83 | -34.01 | -31.15 | -37.35 |
| % Growth | 85.8% | -9.2% | 16.6% | – |
| EPS Diluted | -4.83 | -34.01 | -31.2 | -37.35 |
| Weighted Avg Shares Out | 1,517 | 263 | 48 | 43 |
| Weighted Avg Shares Out Dil | 1,517 | 263 | 48 | 43 |
| Supplemental Information | – | – | – | – |
| Interest Income | $56 | $2 | $0 | $1 |
| Interest Expense | $0 | $0 | $732 | $805 |
| Depreciation & Amortization | $4,219 | $9,428 | $0 | $0 |
| EBITDA | $107 | $480 | -$753 | -$806 |
| % Margin | – | – | – | – |